Details for New Drug Application (NDA): 009376
✉ Email this page to a colleague
NDA 009376 describes SANDRIL, which is a drug marketed by Lilly and is included in two NDAs. Additional details are available on the SANDRIL profile page.
The generic ingredient in SANDRIL is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
The generic ingredient in SANDRIL is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
Medical Subject Heading (MeSH) Categories for 009376
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.25MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
